Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C44H50N4O2.2I |
| Molecular Weight | 920.7023 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[I-].[I-].OC\C=C1\C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1C5=CN6[C@H]7C(=CN([C@H]35)C8=C4C=CC=C8)[C@H]9C[C@H]%10[C@@]7(CC[N@@+]%10(CC=C)C\C9=C\CO)C%11=C6C=CC=C%11
InChI
InChIKey=YKHPPEALFSRPGH-GKLGUMFISA-L
InChI=1S/C44H50N4O2.2HI/c1-3-17-47-19-15-43-35-9-5-7-11-37(35)45-26-34-32-24-40-44(16-20-48(40,18-4-2)28-30(32)14-22-50)36-10-6-8-12-38(36)46(42(34)44)25-33(41(43)45)31(23-39(43)47)29(27-47)13-21-49;;/h3-14,25-26,31-32,39-42,49-50H,1-2,15-24,27-28H2;2*1H/q+2;;/p-2/b29-13-,30-14-,33-25-,34-26-;;/t31-,32-,39-,40-,41-,42-,43+,44+,47-,48-;;/m0../s1
| Molecular Formula | HI |
| Molecular Weight | 127.91241 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C44H48N4O2 |
| Molecular Weight | 664.8775 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 10 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7818127Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17722904 | https://goo.gl/8mllN4 | https://www.drugs.com/international/alcuronium-chloride.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7818127
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17722904 | https://goo.gl/8mllN4 | https://www.drugs.com/international/alcuronium-chloride.html
Alcuronium (diallylnortoxiferine) is a semi-synthetic substance prepared from C-toxiferine I a bis-quaternary alkaloid obtained from Strychnos toxifera. Alcuronium is a neuromuscular blocking (NMB) agent, alternatively referred to as a skeletal muscle relaxant. Alcuronium is used for endotracheal intubation and to produce muscle relaxation in general anesthesia during surgical procedures. The pharmacological action of alcuronium is readily reversed by neostigmine, and it produced little histamine release. The major disadvantage of alcuronium is that it elicits a vagolytic effect produced by a selective atropine-like blockade of cardiac muscarinic receptors.
Originator
Sources: https://goo.gl/8mllN4
Curator's Comment: # F. Hoffmann-La Roche & Co., A.-G.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2492 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17722904 |
4.1 µM [IC50] | ||
Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17722904 |
18.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8678278 |
Primary | Alloferin Approved UseIndications. Alcuronium (Cl) is primarily indicated in conditions like Adjunct to anesthesia, Neuromuscular blockade. |
Sample Use Guides
Adult: Initially, 150-250 mcg/kg; additional doses of 30 mcg/kg may be given as needed.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961078
Left atria were mounted in organ baths containing 20 ml of oxygenated Tyrode’s solution. The preparations were preloaded with 5 millinewton and electrically stimulated via platinum contact electrodes at 3 Hz with rectangular pulses of 5-ms duration. The voltage was 1.5-fold over the threshold of excitation amounting to about 2 V. Contraction force (CF) was recorded isometrically. After an equilibration period of 60 min, a cumulative concentration/effect curve for the negative inotropic action of the agonist under study was recorded. Each agonist concentration was applied for 10 min, a period sufficient to obtain equilibrium effects. Contraction force was expressed as the percentage of the value found at the end of the equilibration period. The agonist was removed from the organ bath over a period of 30 min by replacing the Tyrode’s solution with fresh solution every 10 min. Thereafter, the preparation was preincubated with the Alcuronium for 60 min before another agonist concentration/effect curve was measured in the presence of the Alcuronium. Contraction force was expressed as the percentage of the value at the end of the preincubation period with the Alcuronium. The agonist was washed out using Tyrode’s solution still containing the Alcuronium in the concentration as before. After 30 min of washout, the concentration of the Alcuronium was increased, and, after a preincubation phase of 60 min, another concentration/effect curve of the agonist was measured.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:53:25 GMT 2025
by
admin
on
Mon Mar 31 19:53:25 GMT 2025
|
| Record UNII |
R00D63G99B
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
25389-91-7
Created by
admin on Mon Mar 31 19:53:25 GMT 2025 , Edited by admin on Mon Mar 31 19:53:25 GMT 2025
|
PRIMARY | |||
|
m1484
Created by
admin on Mon Mar 31 19:53:25 GMT 2025 , Edited by admin on Mon Mar 31 19:53:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
76956515
Created by
admin on Mon Mar 31 19:53:25 GMT 2025 , Edited by admin on Mon Mar 31 19:53:25 GMT 2025
|
PRIMARY | |||
|
R00D63G99B
Created by
admin on Mon Mar 31 19:53:25 GMT 2025 , Edited by admin on Mon Mar 31 19:53:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |